People who have recently used cannabis may be more likely to experience memory deficits or difficulties with cognitive function than those who do not use the drug, a recent study suggests.
Columbia Care Inc. announced the initiation of a research study designed to optimize the use of the company’s precisely manufactured, pharmaceutical-quality medical cannabis products through the identification of genetic factors affecting their safety and efficacy.
GW Pharmaceuticals Plc said the company’s drug Epidiolex was successful in treating seizures in patients with a rare form of childhood epilepsy called tuberous sclerosis complex during a late-stage trial.
